Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Modulation of visceral fat by estrogens after menopause

Trial Profile

Modulation of visceral fat by estrogens after menopause

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Conjugated estrogens (Primary) ; Medroxyprogesterone (Primary) ; Raloxifene (Primary)
  • Indications Menopausal syndrome
  • Focus Pharmacodynamics
  • Acronyms AFTER
  • Most Recent Events

    • 15 Nov 2006 Status change
    • 30 Oct 2006 New trial record.
    • 01 Feb 2006 Primary endpoint 'Mass-of-body-fat' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top